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ABSTRACT: Human Papillomaviruses are present in virtually all 
cases of cervical cancer and are also linked with anogenital warts 
and other precancerous lesions which can be primarily prevented 
by HPV vaccination. We searched the PubMed, Scopus, Web of 
Science and Embase databases (between January 1st, 2011 and 
February 28th, 2017) and WHO (World Health Organization) 
and countries’ health organizations websites for data on HPV 
vaccination programs and its effectiveness. For the review on 
the Brazilian Immunization program, we additionally searched 
SciELO database and websites of the Brazilian Ministry of 
Health and the Information System of the National Immunization 
Program (SI-PNI). As of April 2017, about 40% of the countries 
had introduced HPV vaccines in their national immunization 
programs, targeting almost always children and teenage females 
between 9 and 13 years of age. Most of these are high-income 
countries but low- and middle-income countries are recently 
implementing the vaccination program with financial support of 
public and private organizations. Since the introduction of HPV 
vaccination, numerous articles present data on its effectiveness 
in real world supporting the effectiveness of an immunization 
program in the prevention of HPV infection and related diseases 
in both genders. The Brazilian HPV vaccination program 
began in 2014 for 9-13 years old girls and has recently been 
expanded to include boys and young males. This review aims 
to update information on HPV vaccination programs worldwide 
highlighting the Brazilian immunization program. Data on the 
impact and effectiveness of HPV vaccines on infection and related 
diseases is presented. Moreover, the reasons for different coverage 
rates, reflected in low-vaccine uptake, are discussed. Finally, the 
present review addresses the socioeconomic barriers as well as 
the key determinants of long-term program success and strategies 
to improve access and adherence to HPV vaccination. 
Keywords: Condylomata acuminata; Papillomaviridae; Mass 
vaccination; Papillomavirus vaccines; Health impact assessment; 
Uterine cervical neoplasms.
RESUMO: O Papilomavírus Humano (HPV) está presente em 
praticamente todos os casos de câncer do colo do útero e também 
em verrugas anogenitais e outras lesões pré-cancerígenas diversas, 
que podem ser prevenidos primariamente via vacinação. Até abril 
de 2017, cerca de 40% dos países já haviam introduzido a vacina 
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de HPV em seus programas nacionais de imunização, tendo por 
alvo quase sempre meninas entre 9 e 13 anos de idade. A maioria 
desses países são de alta renda, mas países de média e baixa renda 
têm implementado recentemente programas de vacinação com 
o apoio de organizações de financiamento públicas e privadas. 
Desde a introdução da vacinação de HPV, inúmeros artigos 
apresentam dados sobre sua efetividade no mundo real, apoiando 
a efetividade de um programa de imunização na prevenção da 
infecção e na redução das doenças relacionadas ao HPV em 
ambos os sexos. O programa brasileiro de vacinação contra o 
HPV iniciou-se em 2014 para meninas de 9 a 13 anos de idade e, 
recentemente, foi ampliado para meninos. Este artigo de revisão 
visa atualizar os dados de implementação de vacina de HPV em 
diferentes países do mundo, enfatizando o programa brasileiro. 
Além disso, são apresentados os dados de impacto e efetividade 
da vacina de HPV em relação à redução de infecções e doenças 
causados pelos tipos de HPV contidos nas vacinas. Ainda, 
são apontadas as razões para as diferentes taxas de cobertura 
e dificuldades observadas na implementação dos programas, 
considerando barreiras sociais e econômicas. Finalmente, são 
discutidos os principais determinantes de sucesso a longo prazo 
e estratégias para melhorar o acesso e a aderência aos programas 
de vacinação.
Descritores: Condiloma acuminado; Papillomaviridae; Vacinação 
em massa; Vacinas contra Papillomavirus; Avaliação do impacto 
na saúde; Neoplasias do colo do útero.
INTRODUCTION
Human papillomaviruses (HPV) are the most common sexually transmitted virus, with 
infection occurring mainly through sexual intercourse and 
soon after the first exposure1,2, with a lifetime probability 
of infection as high as 80%3. Most infections, which occur 
in epithelial cells4, are asymptomatic and self-limited, but 
persistent and recurrent infections can lead to HPV-related 
lesions and cancer3,5. In many women, natural infection 
does not mount an immune response capable of preventing 
subsequent infections1. 
HPVs are present in virtually all cases of cervical 
cancer and have also been linked with anogenital warts 
and precancerous lesions that can lead to head and neck, 
penile and anal cancers1,2,4,6. The incidence of these types 
of cancer is significant worldwide, but especially in less 
developed countries, where the prevalence of infection and 
lack of diagnosis and treatment are elevated1,7.
Figure 1. Global estimated age-standardized rates of incident cases of cervical cancer8
There are two main strategies for prevention of HPV-
related cancers: HPV vaccination (primary prevention) and 
screening (secondary prevention)9. There are currently three 
types of HPV vaccines available: types of HPV vaccines 
available: Cervarix®, bivalent (HPV 16/18); Gardasil®, 
quadrivalent (HPV 6/11/16/18); and Gardasil 9®, 
83
Rev Med (São Paulo). 2018 jan.-fev.;97(1):81-97.
nonavalent (HPV 6/11/16/18/31/33/45/52/58)7. Prevention 
of cancer is more effective when HPV vaccination occurs 
before exposure to the virus10.
The bivalent vaccine prevents the acquisition of the 
virus types 16 and 18, that are linked to 70% of the cervical 
cancer cases, also known as high risk types, and promotes 
limited cross protection against other genotypes6,10, as does 
the quadrivalent vaccine6. The HPV genotypes 6 and 11 are 
responsible for about 90% of all anogenital warts3,11 and 
are also linked with recurrent respiratory papillomatosis5. 
The infection with these last two genotypes is prevented 
by vaccination with quadrivalent and nonavalent HPV 
vaccines. The nonavalent vaccine is expected to increase the 
protection6, covering the HPV types related to anogenital 
warts, recurrent respiratory papillomatosis and high-risk 
types infection that can lead to low- and high-grade cell 
abnormalities and cancer5. 
An HPV vaccine was first introduced in a national 
immunization program in the end of 20061,12. As of April 
2017, about 40% of countries have introduced HPV 
vaccines in their national immunization programs, targeting 
mainly young females - teenage and infant girls between 9 
and 13 years of age. As most cases of HPV-related cancer 
afflict women and there is evidence of herd immunity, males 
are usually excluded from these programs13. However, 
gender-neutral vaccination seems to be superior than female 
only, additionally promoting equity and equal access to 
healthcare3,6.
Few low and middle-income countries (LMICs) 
have implemented the HPV vaccine into their national 
immunization program due mostly to funding and cost of 
the vaccine, logistical and resource barriers, and cultural 
and political issues related to vaccination14. 
Since the introduction of HPV vaccination in national 
immunization programs, numerous articles presenting data 
on its impact in real world have been published, supporting 
the effectiveness of an inclusive immunization program, 
preventing infection from spreading and demonstrating 
potential for reducing cancer incidence in both genders1,15. 
However, the vaccines available, the target groups and 
the coverage vary between - and within - countries in 
accordance to its population and economic characteristics. 
Moreover, the effectiveness of the vaccination programs is 
being measured differently throughout the world, analyzing 
outcomes such as incidence of genital warts and cervical 
lesions, as well as genotypes of HPV present in normal 
smears and lesions. These observations highlight the need 
of a critical analysis of the publications as to evaluate the 
results obtained by the HPV national vaccination programs 
in females as well as in the male population. 
In 2014, Brazil implemented a wide HPV 
immunization program, initially aimed at 9 to 13 years old 
girls and recently expanded to young boys, besides especial 
groups such as transplanted and HIV-positive adults. After 
delivery of first dose, the program exhibited high coverage 
rates, surpassing the initial target of vaccinating 80% 
of girls in the established age range. However, from the 
second dose in 2014, indicators presented a sharp decrease, 
showing disappointing results in 2015 and 2016. This 
review describes the structure of Brazilian immunization 
program against HPV, including eligible groups, age ranges, 
schedules and coverage rates since 2014. The effectiveness 
of HPV vaccination in Brazil is still to be assessed, since 
it requires a longer period of evaluation, yet few studies 
evaluating practical outcomes are already in progress. 
Therefore, this article focuses on the main reasons for the 
low vaccine uptake observed countrywide and proposes 
feasible strategies to improve access and adherence to HPV 
vaccine. Finally, the key determinants of the long-term 
program success are briefly discussed. 
METHODS
We performed a search of papers published 
from January 1st, 2011 until February 28th, 2017 in the 
databases PubMed, Scopus, Web of Science and Embase 
for data on HPV vaccination programs and its effectiveness 
using the keywords: HPV; vaccination; effectiveness; 
national immunization programs. We also searched the 
website of World Health Organization (WHO) and of 
countries’ health organizations for additional information 
regarding immunization programs. The inclusion criteria 
were: publication in English: presentation or review of 
national immunization programs worldwide or real world 
effectiveness. The exclusion criteria were: mathematical 
modelling; clinical trials. 
For the review on the Brazilian Immunization 
program, we additionally searched articles in SciELO – 
with the keywords HPV, vaccine, immunization program, 
Brazil –, and retrieved information from the databases 
of the Brazilian Ministry of Health and the Information 
System of the National Immunization Program (SI-PNI) 
related to HPV vaccine coverage in 2014, 2015 and 2016, 
in order to analyze the campaign results. The criteria for 
inclusion were: systematic reviews, reviews and official 
data government, based on real world information. We 
excluded mathematical models and progressions, clinical 
trials, articles not in English or Portuguese language, and 
studies about HPV vaccine itself. Finally, we included 
articles evaluating factors involved in long-term program 
success and investigating the vaccination acceptance in 
specific cities of the country.
National Immunization Programs Worldwide
Cervical cancer is the fourth most common cancer 
among women and the seventh most common cancer 
overall. In 2012, approximately 527,624 women were 
diagnosed with cervical cancer and about 85% occurred 
in developing countries. Almost 9 in 10 cervical cancer 
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deaths occur in such regions16.
For decades, high-income countries have been 
able to implement high-coverage programs for screening 
and treatment of cervical precancer, which are based on 
regular Papanicolaou smears and appropriate treatment of 
precancerous lesions, along with treatment or palliative 
care for advanced cancer17. These have been reducing the 
disease incidence and mortality since the 1970s18, but this 
expensive approach may prove difficult to implement and 
sustain in regions with low resources19,20 where screening 
and treatment programs are not fully available and mortality 
rate is still high.
More than 70 countries have introduced HPV 
vaccination in their National Immunization Programs, of 
which 30 are low- and middle-income countries21.
Figure 2. Countries with HPV vaccine in national immunization program in 201721
After the first HPV vaccine was licensed in 2006, the 
first countries to introduce the HPV vaccine were the USA, 
Australia, Canada, and some European countries22. Panama 
in Latin America, Bhutan in Asia and Rwanda in Africa 
were the first LMICs that introduced HPV vaccination. 
Cost prevented the introduction of the vaccines into 
LMICs. Further impediments to the introduction of HPV 
vaccines included the challenges of the target age group 
and competing health priorities14.
High income countries
The United States, Australia, Canada and the United 
Kingdom (UK) were among the first countries to implement 
HPV vaccine into their national immunization programs. In 
Europe, the number of countries having introduced vaccine 
increased from 3 in 2007 to 28 in April 2017. While all 
country programs target young adolescent girls, specific 
target age groups vary. Different health care systems and 
infrastructure have resulted in varied implementation 
strategies.
Low- and middle-income countries
Within the first 10 years after vaccines became 
available, few LMICs had introduced HPV vaccine. The 
main reason was budgetary restrictions due to the high 
vaccine cost. Bhutan and Rwanda were the first low-
income countries to implement national immunization after 
receiving vaccine through donation programs in 2010 and 
2011, respectively23,24. Introduction of vaccine in LMICs 
requires a variety of factors and cooperation between 
international agencies and manufacturers25. 
In most programs, a school-based approach is 
predominantly used to deliver the vaccine to the target 
adolescents with additional efforts using field clinics, 
and primary health centers to cover girls who missed 
vaccination and do not attend schools. 
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Implementation’s Barriers for HPV Vaccination and 
Main Financing Mechanisms for LMICs
Significant progress has been made to improve the 
affordability of HPV vaccine to LMICs through financing 
mechanisms, including GAVI, the Vaccine Alliance, and 
the Pan American Health Organization (PAHO) Revolving 
Fund. 
The Global Alliance for Vaccines and Immunizations 
(GAVI) was created in 2000 to support the implementation 
of vaccination programs to reduce child mortality rates 
in the world’s poorest countries through funds from 
donors worldwide, and decides which vaccines would 
be the most efficacious and cost-effective to introduce to 
these countries26. Although the GAVI Alliance prioritized 
the HPV vaccine in 2009, it was not until 2012 that 
both HPV vaccines were first made available to GAVI-
eligible countries, thanks in part to tiered pricing by the 
manufacturers, which dramatically reduced the cost of each 
dose, that is now available for the poorest countries for 
U$4.50 per dose27. GAVI may cover the costs for vaccines 
and some logistical costs, but the states are responsible 
for the delivery. Introduction of vaccine requires capacity 
for storage, transport, and personnel, which might be 
lacking in the country, further complicating the launch of 
the vaccine program. Due to infrastructure and capacity 
issues, many GAVI countries may delay the introduction 
of this vaccine28.
The PAHO Revolving Fund was established in 
1977 as a mechanism for procurement of supplies and 
equipment necessary for sustained delivery of vaccines. By 
buying in bulk, the Fund greatly improves its purchasing 
power29. Through this mechanism, a price of US$9.80 for 
the quadrivalent and U$8.50 for the bivalent vaccine per 
dose has been recently achieved30.
Nowadays, 80% girls aged 9-13 years in the Latin 
American region have access to HPV vaccination through 
national immunization programs due to political will and 
the negotiated purchase of the vaccines31. 
Table 1 summarizes the information on HPV 
vaccination in main countries in different regions of 
the world. The unavailability of updated information in 
government official websites and health organizations was 
the leading difficulty faced in data gathering. This review 
article does not have the pretension to update on HPV 
national immunization programs in all countries but to 
provide an overview and illustrate the difference between 
the HPV vaccine offered through national programs in 
high income countries and low-middle income countries.
Table 1. National HPV Immunization Programs Worldwide
Country Year of introduction Gender
Primary target 
age group Delivery strategy Dosage Vaccine References
Americas    
Argentina 2011 F&M 11 Health Center 2 2v 32
Brazil 2014 F&M 9-13 F; 12-13 M School and Health Center 2 4v 33
Canada 2007–2009 F&M 9-14 School 2 2v; 4v 34
Chile 2014 F 9 School 2 4v 35
Colombia 2012 F 9-17 School and specials campaigns 2 4v 36
Mexico 2012 F 9-11 School and Health Center 2 - 37
Paraguay 2013 F 12 School 3 4v 38
Panama 2008 F&M 10 School and Health Center 2 4V 39
Peru 2011 F 9-13 School 2 4v 40
United 
States 2006 F&M 11-12 Health Center 2 9v 41
Uruguay 2013 F 12 Health Center 3 4v 42
Europe
Austria 2014 F&M 9-12 School 2 9v 43
Denmark 2009 F 12-18 Health Center 2 2v 44
France 2007 F 11-14 Health Center 2 2v; 4v 45
Germany 2007 F 9-14 Health Center 2 2v; 4v; 9v 46
Ireland 2010 F 13-14 School 2 4v 47
Portugal 2008 F 10 Health Center 2 9v 48
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Country Year of introduction Gender
Primary target 
age group Delivery strategy Dosage Vaccine References
Table 1. National HPV Immunization Programs Worldwide               Continuation
United 
Kingdom 2008 F 12-13 School 2 4v 49
Western Pacific
Australia 2007 F&M 12-13 School 3 4v 50
Malaysia 2010 F 13 School and Health Center 2 - 51, 52
New 
Zealand 2008 F&M 9-26 School and Health Center 2 9v 53
Africa
Angola 2015 F 10-14 Health Center 3 - 54
Rwanda 2011 F 11-12 School 2 - 51, 52
South Africa 2014 F 9 School 2 4v 51, 52
South Asia
Bhutan 2010 F 12 School and Health Center 3 4v 23
Impact and effectiveness of HPV vaccination as a public 
health policy
A total of 19 articles were included in the review 
of vaccination programs’ impact and effectiveness, all 
conducted in high-income countries. 
HPV genotypes
As mentioned before, the bivalent vaccine (HPV 
16/18) offers protection against infection with high risk 
types, while the quadrivalent vaccine (HPV 6/11/16/18) 
also protects against the genotypes responsible for most 
anogenital warts and respiratory papillomatosis. 
In Belgium, after testing cervical cell samples for 
HPV genotyping, it was found that the risk of infection with 
HPV vaccine types was significantly lower for vaccinated 
women aged 18-29 years, except for infection with HPV 
11, and there was a higher risk of infection with other 
high-risk HPV types55. 
The United Kingdom introduced the bivalent HPV 
vaccine in 2008, switching to the quadrivalent in 2012; 
however, the articles included in this review are from the 
period of the bivalent vaccine56-59. In Scotland, a reduced 
prevalence in HPV 16 and 18 was reported, specially 
among women who received all three vaccine doses, 
with cross-protection against HPV 31, 33 and 4558. The 
annual prevalence of HPV 16/18 in cervical cell samples 
decreased with each year since vaccine introduction among 
vaccinated women, with an HPV 16 and 18 prevalence 
even lower in younger women, in those who had received 
more doses of the vaccine57. Similar results occurred in 
England, pronouncedly in the 16-18 and 19-21 years 
age groups56. National data from all countries in United 
Kingdom confirms a decreased prevalence in HPV 16/18, 
markedly in women between 16 and 18 years of age, with 
similar results for other HPV genotypes in comparison 
with previous studies59. Women from less deprived areas 
and those who were vaccinated at a younger age also 
had lower odds of infection with these HPV genotypes57. 
There was also evidence of cross-protection for HPV 3156 
and for HPV 31, 33 and 4557, and of herd immunity for 
unvaccinated women56,57. 
The Australian HPV vaccination program used the 
quadrivalent vaccine since its start in 2007, vaccinating 
young women between 10 and 26 years of age60. An overall 
decrease in HPV prevalence was observed, with greater 
differences in the vaccine-targeted HPV genotypes, even 
amongst unvaccinated women60. In the post-vaccination 
period of observation, infection with vaccine-targeted 
HPV types was highest among the unvaccinated women 
and lowest in the fully vaccinated group60.
A different approach, in the United States of 
America, revealed significant declines in CIN2+ and 
CIN 3+ lesions attributable to HPV-16/18 in women who 
received at least one quadrivalent vaccine dose within 6 
years from the start of the vaccination program12.
Genital and anal warts
Anogenital warts are important short term indicators 
of impact and effectiveness of HPV vaccination programs, 
since the median development time for these lesions is 
around 3 months after infection with HPV types 6 and 
11, whilst the development of cervical cancer occurs over 
several years or decades4,11. Only the quadrivalent and 
nonavalent vaccines offer protection against HPV 6 and 
11 and, in this case, only data on the quadrivalent vaccine 
was recovered.
A total of 4 studies focused on genital warts’ 
incidence in both genders3,4,61,62; another measured the 
incidence of anogenital warts in both men and women11. 
The results of vaccination over men reflect herd immunity, 
since only women were vaccinated in the considered period. 
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An additional study was conducted in Canada, with girls 
before and after vaccine exposure, calculating absolute 
and relative risks of developing cervical dysplasia and 
anogenital warts, with an apparent reduction in the latter63; 
however, the authors deemed these last results imprecise. 
In all other cases, the authors were able to ascertain that the 
results were most likely due to HPV vaccination and not to 
possible behavioral changes by assessing the incidence of 
Chlamydia infections3,4,11, 61,62 and other sexually transmitted 
diseases61, as a proxy for behavior.
In Denmark, a significant decrease in anogenital 
warts was observed among 15- to 24-year-old men and 
women11. After a second catch-up program was instituted 
for women up to 27 years, progressive smaller reductions 
were observed in women aged 20-35 and in men aged 20-
29, with no significant change in genital warts incidence 
for women aged 36 or older and for men aged 30 years 
or older3. 
Similar results were reported in Belgium, with an 
overall 8.1% reduction on the incidence of genital warts 
in men and women with ages between 18-59 years4. The 
quadrivalent vaccine was most effective when all three 
doses were administered, with significant decreases 
even after one or two doses and higher effectiveness 
when women were vaccinated at a younger age (before 
completing 18 years), when prior exposure to HPV is less 
likely4.
In Australia, an overall reduction of 59% in genital 
warts incidence in women was observed, though no 
significant decrease was found in females that were not 
eligible for free vaccination61. In heterosexual men, there 
was a 28% decrease in total, but no significant change in 
older ages and in men who have sex with men (MSM)61. 
A subsequent study identified decreases of up to 92.6% in 
genital warts in women aged up 30 years, but no significant 
decline in older women62. There were no diagnosed genital 
warts in vaccinated women under the age 21 in 2011 and 
less than 1% of women who were 21 years old or younger 
in that year were found to have genital warts, against 10.5% 
in 2006 (pre-vaccination)62. In heterosexual men, a similar 
pattern was observed, with up to 81.8% decline in men 
aged up to 30 years, but no significant changes in those of 
30 years or older, while in MSM, a lower overall decline 
of 24.7% was observed62. 
Table 2. Impact of HPV vaccination on anogenital warts in men and women
Country Author
Years since 
vaccine 
introduction
Vaccine 
available Target group
Coverage 
rate
Incidence rate 
after vaccination 
(women)
Incidence rate after vaccination 
(men)
Denmark Sando et al.11 within 3
quadrivalent; 
free
12 years old 
girls; catch up 
at age 16
80% all 
doses
90% first 
dose
aged 15-19: - 67% 
aged 20–24: - 18%
aged 25–29: + 11%
aged 30–34: no 
significant changes
aged 15-19: - 50%
aged 20–24: - 6% 
aged 25–29: no significant 
changes
aged 30–34: + 13%
Denmark Bollerup et al.3 within 5
quadrivalent; 
free
12 years old 
girls; catch up 
at age 15 up 
to 2010 and at 
age 27 from 
2012 on
87-91% at 
least one 
dose
(75% in 
the second 
catch-up 
program)
aged 12-15: - 42.7% 
aged 16-17: - 55.1%
aged 18-19: - 39.0%
aged 20-21: - 20.9%
aged 22-25: - 11.7%
aged 26-29: - 5.5%
aged 30-35: - 3.7%
aged 36+: + 0.4%
aged 12-15: - 24.5% 
aged 16-17: - 36.7%
aged 18-19: - 34.4%
aged 20-21: - 21.0%
aged 22-25: - 8.8%
aged 26-29: - 3.1%
aged 30-35: - 0.8%
aged 36+: + 2.1%
Belgium
Dominiak-
Felden et 
al.4
within 6 quadrivalent; reimbursement
12 to 18 years 
old females 43%
aged 18–59 
(considering both 
sexes): - 8.1%
aged 16-22: - 72.1%
aged 23-30: - 18.8%
aged 31-40: + 20.0%
aged 41-59: + 33.1%
aged 18–59 (considering both 
sexes): -8.1%
aged 16-22: -51.1%
aged 23-30: + 14.2%
aged 31-40: + 10.2%
aged 41-59: + 27.3%
Australia Donovan et al.61 within 3
quadrivalent; 
free
12 years old 
girls; catch-up 
up to the age 
of 26 years
80% first 
dose
70% three-
dose
overall: - 59%
aged 26+: not 
significant
heterosexual overall: - 28%
heterosexual, aged 12-26 years: 
- 39%
heterosexual, aged 26+ years: not 
significant
MSM: not significant
Australia Ali et al.62 within 5 quadrivalent; free
girls aged 
12-13; 
catch-up for 
13-18-year-
old 
schoolgirls 
and 
18-26-year-
old women 
in the 
community
83% first 
dose
80% 
second 
dose
73% third 
dose
aged up to 21 years: 
92.6%
aged 21-30 years: 
72.6%
aged 30+: no 
significant decline 
heterosexual, aged up to 21 
years: - 81.8%
heterosexual, aged 21-30 years: 
- 51.1%
heterosexual, aged 30+: no 
significant decline
MSM: - 24.7%
88
Freitas ACGS, et al. Human papillomavirus vaccination in national immunization programs. 
Cervical cell abnormalities
Since cervical cancer develops over the course 
of years or decades, vaccination impact over cancer 
rates were still not observed. However, it is possible to 
assess the vaccination impact over low- and high-grade 
cervical intraepithelial neoplasia (CIN) and squamous 
intraepithelial lesions (LSILs and HSILs). Both the bivalent 
and quadrivalent vaccines, addopted by most countries to 
date, offer protection against HPV 16 and 18, linked with 
most cases of cervical lesions.
Three doses of the bivalent vaccine lowered the 
incidence of CIN3 and the risk of diagnoses of CIN2 and 
CIN1, but no statistically significant decline in incidence 
was reported with partial immunization in Scotland64, whilst 
in Australia it was found that receiving any number of 
vaccine doses led to lower rates of histologically confirmed 
high-grade cervical abnormalities and lower rates of high-
grade and low-grade cytology diagnoses65. 
A decreased incidence in CIN2+ was observed in 
18 to 20 years old women in USA, but not in older group 
ages66. However, it could not be ascertained whether this 
reduced incidence was due to vaccination, reflecting the 
difficulties of this assessment in the USA66. 
In Sweden, there was evidence of effectiveness 
of vaccination over CIN2+ and CIN3+, with lower 
incidence rates in vaccinated females after three doses 
of the quadrivalent vaccine were administered, more 
evidently when vacciantion occurred at younger ages (up 
to 17 years)67. 
Three different studies from Canada assessing HPV 
vaccine effectiveness over cervical lesions were included 
in this review. The first, conducted in Manitoba, found 
moderate effectiveness over prevention of SILs among 15-
17 year old girls, but lower for other types of lesions (SILs 
and atypical squamous cells of undetermined significance 
- ASCUS) and for other age groups, especially when there 
was a history of abnormal cytology68. In British Columbia, 
a significant decrease in CIN2 and CIN2+ was observed 
in vaccinated 15-17-year-old girls, but not in unvaccinated 
18-22-year-old women69. Finally, in Ontario, data reflected 
reduced dysplasia incidence in vaccinated girls aged 14 to 
17 years63.
Table 3. Impact of HPV vaccination on cervical cell abnormalities
Country Author
Years since 
program 
introduction
Vaccine 
available Target group Coverage rate Results (women only)
Scotland Pollock et al.64 within 4
Bivalent and 
quadrivalent; 
free
12- to 13-year-
old girls; 
catch-up up to 
18 years of age
over 90%
Age group: 20-21 years, three-doses
CIN 1: RR 0.71
CIN 2: RR 0.5
CIN 3: RR 0.45
Australia Brotherton et al.65 within 4
Quadrivalent; 
free Not described over 50%
Any number of doses (1, 2 or 3): lower rates of 
high grade and low grade cytology diagnoses 
and outcomes if doses given before screening 
commencement
USA Hariri et al.66 within 5
Bivalent and 
quadrivalent; 
varies with State
Women 11.6-34.5%
Age group: 18-20 years
CIN2+: Ptrend<.0001
Age group: 21-29 years
CIN2+: Ptrend<.001
Age group: 30- to 39-year-olds
CIN2+: no significant difference
*vaccination contribution not quantifiable
Sweden Herweijer et al.67 within 6
Quadrivalent; 
reimbursement 
(2007-2011); 
free (2012)
Girls aged 
13–17 years 
(2007-2011); 
girls aged 10-
12 years, with 
catch-up doses 
at 13-18 years 
(from 2012 on)
First-dose: 
82% (target 
group); 60% 
(catch-up and 
subsidized 
vaccinations) 
(2014)
Age at vaccination: up to 17 years
CIN2+: VE 75%, IRR 0.25
CIN3+: VE 84%, IRR 0.16
Age at vaccination: 17-20 years
CIN2+: VE 46%, IRR 0.54
CIN3+: VE 57%, IRR 0.43
Age at vaccination: 20-29 years
CIN2+: VE 22%, IRR 0.78 
CIN3+: VE 25%, IRR 0.75
Canada Mahmud 
et al.68 within 4
Quadrivalent; 
free Girls Not mentioned
Age group: 15-17 years
HSILs: VE 35% 
LSILs: VE 21% 
ASCUS: -1% 
Risk reduction for LSL:  24%
Age group: 18 or older
Significance varied with previous lesions and tests
Canada Ogilvie et al.69 within 4
Quadrivalent; 
free
Pre-adolescent 
girls; catch-up 
for adolescents 
girls
58-62%
Age group: 15-17 years (vaccinated)
CIN2+: IRR from 0.91 to 0.36
Age group: 18-22 years (unvaccinated)
CIN2+: IRR from 0.95 to 0.99
Canada Smith et al.63 within 5
Quadrivalent; 
free
Girls aged 9-13 
years ~50%
Age group: 14-17 years
Incidence of dysplasia: -5.70/1000 girls
Relative reduction: 44% (RR 0.56)
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Vaccination effectiveness
Different methodologies were used to assess the 
impact and the effectiveness of HPV vaccination in the 
reviewed studies, which is a challenge for comparing and 
consolidating the obtained results. It was not the objective 
of this review to compare or validate these approaches, but 
to report the main trends. A meta-analysis is recommended 
to enable further conclusions.
A significant reduction in the monitored outcome 
after vaccination was observed in all studies for at least one 
subgroup (according to age, sex and sexual orientation), 
which points to the positive impact of HPV vaccination 
in real-world settings, reducing infection with various 
HPV genotypes and the incidence of lesions, such as 
anogenital warts and neoplasia, mainly in vaccinated 
subjects but also in some unvaccinated populations. 
Thus, herd protection has been observed, prominently in 
heterosexual men of age groups close to the vaccinated 
subjects4, with an accentuated effect with higher coverage 
and expanded target groups. The impact and effectiveness 
of HPV vaccination seems to be higher when the vaccine 
is administered at a younger age, before sexual debut and 
exposure to HPV infection63,65-68.
In the light of these findings, all within 6 years since 
the onset of the vaccination programs, it can be reasonably 
expected to observe further decreases in the incidence of 
HPV-related lesions and neoplasias, with the aging of the 
vaccinated population and the reduced circulation of the 
virus due to the herd immunity effect. Moreover, these 
results herald future reductions in the incidence of HPV-
related cancer as the final effect of the HPV vaccination, 
considering the aging of vaccinated population and the 
time frame (due to latency and repeated infections) of the 
development of cancer1,11,70.
Further studies reflecting data gathered after the 
inclusion of more groups in vaccination programs, such 
as boys and immunosuppressed patients, will reveal 
the impact of the strategy over these target groups and 
the overall population. Also, the real-world impact of 
vaccination over other HPV-related lesions still requires 
more information, specially among men.
HPV vaccination is also expected to have an 
impact over screening methods, with the shift from the 
prevalent cytology (alone or with HPV co-testing) to 
HPV testing, since cervical cancer is expected to have a 
reduced prevalence in the future2,70. Novel policies must be 
considered when higher coverage and longer vaccination 
period are attained2. We expect to see significant changes 
in screening algorithms in the years to come.
The Brazilian Immunization Program against HPV
Program Operation and Vaccination Coverage
In Brazil, cervical cancer is the third most common 
neoplasia among women (excluding non-melanoma skin 
cancer)71 and represents the fourth cause of cancer death 
in Brazilian women, being responsible for 5.448 deaths in 
201472. HPV infection in Brazilian women with normal 
cervical cytology varies between 10.4% and 24.5%73. In 
order to fight cervical cancer using a primary prevention 
strategy, the Brazilian Ministry of Health announced that 
the Unified Health System (SUS) would incorporate the 
vaccination against HPV from March 2014.
Initially, the target population would be girls at 
ages 9-13 years, who would receive free of charge the 
quadrivalent vaccine (against HPV types 6, 11, 16 and 18) 
by stages: in 2014, vaccine would be delivered to girls 
aged 11-13 years old; in 2015, to girls aged 9 -11; and from 
2016 on, to nine years old girls. The goal was to vaccinate 
80% of the cohort, roughly 4.2 million girls in 2014, 4.2 
million in 2015 and 1.3 million in 2016. Administration 
of the three doses would occur under the permission of 
parents or guardians of pre-adolescents according to the 
extended schedule. In order to improve vaccine access, 
the first stage of HPV immunization program took place 
at public and private schools and primary care clinics 
(Unidades Básicas de Saúde - UBSs)74.
The campaign was highly successful during the 
first phase, in 2014. According to the Information System 
of the National Immunization Program (SI-PNI), the first 
dose of the vaccine was given to 4,847,356 girls in the age 
group of 11 to 13 years, reaching a higher coverage than 
initially targeted. In the same year, however, coverage of 
the second dose was significantly lower (40.8%). This 
trend continues to be observed for girls between 9 and 13 
years: in 2015, the first dose was delivered to only 41.1% 
of the younger girls and 22.5% of them received the 
second dose. Between January and October 2016, only 
12% of girls between the ages of 9 and 13 received the first 
dose and, at the same time, around 8.7% were immunized 
with the second dose. Doses applied in previous years 
from the State of Amazonas and the Brazilian Federal 
Capital District and from some municipalities that had 
implemented the HPV vaccine before March 2014 are not 
being computed75 (Figure 3).
In 2016, the Brazilian Ministry of Health decided to 
reduce from 3 to 2 doses the vaccination schedule (except 
girls and women living with HIV) based on evidence that 
antibody responses in girls were non-inferior after 2 doses 
compared to 3 doses76 and to include 14 years-old girls 
who had not taken one or two doses previously, about 
500,000 more girls. Due to such changes, the amount of 
vaccines available allowed the inclusion of boys in the 
program. In 2017, nearly 3.6 million of boys aged at 12-13 
were offered the quadrivalent HPV vaccine in two doses, 
with a 6 months interval between doses. Furthermore, 
about 99,500 HIV-positive boys and men aged 9-26 years 
will also be immunized, under 3-doses schedule (2 and 
6 months intervals after the first dose). In 2018, target 
population will be boys aged 11-12; in 2019, those aged 
10-11; and from 2020, those aged 9-10 (Table 4).
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Figure 3. Brazilian National Coverage of HPV vaccination: 2014 to 201675
Table 4. Eligible Population to Receive Free HPV Vaccination in Brazil77,78
Target Population Age Group Number of Doses Dose Interval
Boys 12 to 13 (2017) 2 0 and 6 Months
Girls 9 to 14 2 0 and 6 Months
HIV-Positive People Men and Women aged 9 to 26 3 0, 2, 6 Months
Transplanted from Solid Organs Men and Women aged 9 to 26 3 0, 2, 6 Months
Transplanted Bone Marrow Men and Women aged 9 to 26 3 0, 2, 6 Months
Oncologic Patients Men and Women aged 9 to 26 3 0, 2, 6 Months
Through these actions, the Brazilian Ministry of 
Health intends to assist around 7.1 million teenagers in 
2017, to reduce incidence of cervical and vulvar cancer 
in women, to prevent penile and anal cancer and genital 
warts among men, and to decrease incidence of mouth 
and oropharynx cancer in both genders79.
Reasons for Low Coverage in Brazilian Immunization 
Program against HPV
Despite the high investment and logistical 
complexity involved in the establishment of the national 
HPV immunization program, the coverage rates are 
disappointing which certainly represents a barrier to the 
program effectiveness. The following discussion addresses 
separately the main reasons for this low performance.
Discontinuance of school-based delivery of vaccines
The interruption of vaccine application in schools 
is being considered one of the central reasons for the 
alarming decline observed in Brazilian vaccination 
coverage levels80. Publications from different countries 
provide evidence of higher vaccine uptake in school-
based programs compared to single health facility-
based models81-85. Firstly, since schools are attended by 
a large proportion of adolescents, adoption of active 
primary prevention - such as the displacement of health 
professionals to the students’ setting - facilitates success 
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on vaccine delivery. Immunization in public health posts 
depend on individual’s initiative, relying on advertising 
campaigns for the success or failure of the action. 
Secondly, schools also provide a favorable environment 
for educational measures, which should contribute 
to students’ awareness of HPV and related diseases, 
highlighting the importance and usefulness of the vaccine 
and also deconstructing myths that generate uncertainty 
and fear. As exemplified by Fregnani and collaborators, 
educational interventions addressed to parents (“Parents 
Meeting”) and pupils (“Educational Week”) substantially 
contributed to the very high three-dose completion rate 
of 97.2% obtained in this demonstration study86. This 
supports the need for integration between health and 
education system to achieve better vaccination indicators. 
On the other hand, there have been reports that school-
based program may lead to inequities in vaccine uptake, 
due to poor access to education and differences in school 
attendance among different regions countrywide87. This 
does not seem to be the case for Brazil, since high rates 
of coverage were obtained in the beginning of the HPV 
immunization programs.
Differently from Brazilian childhood vaccination 
- performed during first years of child’s life and 
internationally recognized for its excellent coverage 
and acceptance results88, HPV immunization occurs 
outside the usual age range, representing another relevant 
obstacle. Additionally, time span between vaccine doses 
may confuse parents and physician contributing to low 
compliance89. For this reason, it seems more appropriate 
to the Brazilian reality to associate vaccination in schools 
with traditional UBS-based immunization, potentially a 
more effective strategy for developing countries90.
Distorted fears and perceptions about the vaccine
Despite the fact that high efficacy and safety of the 
vaccine have already been demonstrated, identification of 
isolated cases of adverse effects in the country combined 
with indiscriminate spread of rumors in the media and 
social networks produced a feeling of insecurity. Surveys 
performed with parents or guardians of pre-adolescent 
girls in studies conducted in Barretos86 and in Roraima91, 
showed that the main reason for refusing to authorize 
vaccination was fear of adverse effects. This peculiarity 
is not exclusive of Brazil; other countries, such as Japan92 
and United States93, also face this challenge.
From June 2006 to March 2013, approximately 
56 million doses of the quadrivalent HPV vaccine were 
distributed in the United States and, in the same period, 
a total of 21,194 adverse events were reported to the 
Vaccine Adverse Event Reporting System (VAERS), of 
which 92.1% were classified as non-serious, reinforcing 
vaccine safety (94). Even in the face of abundant evidence 
about benefits of HPV immunization and its low risks, 
strengthening of anti-vaccine movements has a negative 
influence on population coverage rates95,96.
Misperceptions and some prejudices may also 
be an obstacle to user’s adherence. In Brazil, a cross-
sectional study conducted in 2016, in Roraima, submitted 
797 parents to a questionnaire assessing knowledge, 
adherence and perceptions about HPV and HPV vaccine. 
In this survey, parents who believed vaccine offered for 
free by the SUS was of poor quality had a significantly 
greater risk of not authorizing vaccination91. In addition, 
since this vaccine is related to a sexually transmitted 
infection, there is a greater contribution of socioeconomic 
factors, cultural differences, individual opinions and even 
a low level of trust in public healthcare.
Lack of knowledge about HPV and HPV vaccine
According to several studies, worldwide knowledge 
about HPV is generally poor (97; 98); in Brazil, the 
few existing publications reveal the same situation99-101. 
Although it seems intuitive at first, association between 
poor knowledge about HPV and the low acceptability of 
the vaccine remains controversial: studies from Turkey102, 
Netherlands103, Indonesia104 and United States105 found 
high vaccine acceptability even in a population sample 
with limited knowledge of HPV and cervical cancer; on 
the other hand, some authors classify awareness about 
HPV as a predictor of intention to receive the vaccine106. 
Despite such disagreements, nearly all of these studies 
highlight the importance of improving educational 
measures related to HPV and HPV vaccine.
Popular beliefs about the vaccine may have a 
stronger influence on its compliance than the formal 
understanding of the virus and its associated diseases107. 
One example is the perception of immunization as 
beneficial, associated with increased approval of the 
HPV vaccine in different studies103,108,109 worldwide. In 
Brazil, one study found that the factors with greatest 
influences on acceptability were knowledge that HPV 
infection is common, that the vaccine is effective and that 
its purpose is to prevent cervical cancer. Moreover, the 
parents’ understanding that the HPV vaccine is important 
for the health of their daughters was considered a positive 
predictive factor for vaccination91. However, even in an 
educated population, implementation of a vaccination 
program does not guarantee a satisfactory level of 
knowledge without adequate advertising strategy86. For 
this reason, it is imperative that vaccination campaigns 
provide the population and health professionals with 
relevant information which takes into account not only 
technical aspects related to HPV and cervical cancer, but 
also the relevance of this vaccine, its safety, its efficacy, 
its availability and the age groups of interest. Therefore, 
the central role of schools is again emphasized, since pre-
adolescents may receive this information at classroom and 
transmit it to parents at home86, increasing the likelihood of 
adherence to the vaccine. Finally, vaccination campaigns 
must be adequate to the reality of each region, given the 
cultural heterogeneity of the Brazilian population. Thus, 
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further studies are warranted.
Perspectives for the Brazilian HPV immunization 
program
The Brazilian HPV immunization program may 
be considered recent when compared to countries with 
greater experience in this field, such as Australia, Sweden 
and Denmark. In addition, the great extension of the 
country, socioeconomic differences between regions 
and barriers to access education and health make the 
challenge of vaccinating adolescents even more complex, 
both logistically and financially. Some factors can be 
considered decisive for the long-term success of the 
program, as follows.
Improving Vaccine Uptake
Vaccine administration to a high number of people 
is a key element in the protective effect of immunization, 
obtained by the so-called “group immunity”. As shown, 
vaccination coverage in Brazil is still far from the aimed 
target aimed. Therefore, a combination of strategies 
should be implemented110:
1) integration between ministries of health and 
education for maintenance of vaccination in schools at 
large, evaluated as more effective than administration in 
health care centers only;
2) development of educational strategies to 
increase awareness and knowledge about HPV and 
HPV vaccine and to avert fears and misperceptions. 
Such actions should ideally take place in schools, yet 
other media resources may be included in appropriate 
dissemination of information, especially television, radio, 
social networks and government pages;
3) formulation of official guidelines for physicians 
– providing scientific evidence about efficacy, safety and 
eligible population for HPV vaccine – to stimulate the 
medical recommendation.
Sustainability of the program 
The long-term sustainability of national program 
also depends on organizational components. One is the 
technology-transfer for self-sufficient vaccine production 
by the country. The Brazilian government has been 
working on this agenda since 2013, when the US company 
Merck, Sharp & Dohme (MSD) established a technology-
transfer agreement with Butantan Institute aiming to 
produce the vaccine at a lower cost111. Another item is 
implementation of a national electronic immunization 
registry, a beneficial tool for monitoring vaccination 
performance112, providing information on the number 
of delivered doses, coverage rates, budget estimates 
and locations with greater deficiency113. The Brazilian 
Information System of the National Immunization 
Program (SI-PNI), however, still lacks technological 
improvements, because many UBSs do not dispose the 
resources to its access; moreover, in many school-based 
vaccination records to the system are registered on paper 
forms114. Thus, a combined strategy aimed to achieve 
improvements in these logistical areas – independence in 
vaccine production and integration of vaccine monitoring 
systems – is crucial for the continuation of the program in 
the next years.
CONCLUSION
Costs to implement HPV vaccination programs for 
many LMICs remain an important ongoing investment and 
potential financial barrier. Although significant progress 
has been made to achieve lower prices for the vaccine, 
many middle-income countries are ineligible for financial 
alternatives offered through GAVI. Besides cost-related 
issues, these countries may experience sociocultural, health 
systems and political barriers to deliver and sustain HPV 
vaccination programs and opportunities to support these 
countries should be explored.
HPV vaccination has yielded positive results, 
markedly reducing the incidence of anogenital warts, 
HPV infection and premalignant cervical lesions, a clear 
and steady demonstration of the effectiveness of HPV 
prophylactic vaccination. It should be noted that, in 
spite of evidence of herd immunity among unvaccinated 
subjects, it is limited to females and heterosexual males 
in age groups close to that of the vaccinated subjects and 
dependent of high vaccine coverage: MSM and several 
high-risk groups, as immunosuppressed patients, are still 
being overlooked by the predominant HPV vaccination 
policies worldwide, perpetuating inequality in health care. 
Although high coverage could potentially extend herd 
immunity, attaining the necessary rates is a challenge for 
most countries. Besides, it does not prevent from exposure 
from potentially infected individuals of different origins 
and vaccination status. Therefore, it is recommended 
that HPV vaccination is extended at least to males and 
immunosuppressed patients. 
In Brazil, it is important to emphasize the great 
benefit of providing immunization at the national level 
as a primary prevention measure against cervical cancer, 
a highly prevalent neoplasm among women. However, 
vaccination against HPV still faces several challenges: 
the country’s large territorial extension, socio-economic 
barriers, and difficulties in articulating the health system. 
Moreover, there are problems inherent to the program 
itself, such as the interruption of vaccination in schools, 
fears and distorted perceptions of users and the general 
lack of knowledge about HPV and the vaccine. Therefore, 
Brazilian authorities must adopt specific strategies to 
overcome these issues and reestablish high coverage rates. 
Thus, more studies should be carried out, focusing not only 
on analysis of problems faced by the program but also 
on the evaluation of its effectiveness, such as monitoring 
the HPV infection and HPV-related disease prevalence 
countrywide. 
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